Tempest Therapeutics, Inc. (TPST) is listed on NASDAQ in the Manufacturing sector. This page tracks real-time TPST price, technical indicators including RSI, MACD, and the 52-week range, plus fundamentals, earnings history, and recent insider trading activity.
Technical Analysis
RSI (14) 70.6 Overbought
Market Cap $18.1M
Volume 147.7K
Fundamentals — 10-Q Q1 2026
Revenue --
Net Income $-27.7M
EPS $-2.53
P/E Ratio -0.5x
Earnings
Recent Insider Trades
| Name | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Angel Matthew | CEO and President | Buy | 231,482 | $2.16 | $500,001 | 2026 Mar 24 |
| Angel Matthew | CEO and President | Buy | 231,482 | $2.16 | $500,001 | 2026 Mar 24 |
| Versant Vantage II, L.P. | 10% Owner | Sell | 787,999 | $1.23 | $966,799 | 2024 Aug 12 |
| Brady Stephen R | President and CEO | Buy | 35,000 | $2.11 | $73,850 | 2024 Jul 3 |
| Whiting Samuel | Chief Medical Officer | Buy | 4,672 | $2.13 | $9,951 | 2024 Jul 2 |
| Trojanowski Justin | Corporate Controller | Buy | 7,500 | $2.16 | $16,200 | 2024 Jun 28 |
| Woiwode Thomas | Director | Buy | 2,118,644 | $2.36 | $5.0M | 2022 Apr 29 |
| Dubensky Thomas W. | President | Buy | 2,000 | $4.78 | $9,560 | 2022 Jan 7 |
| Whiting Samuel | Chief Medical Officer | Buy | 1,700 | $4.80 | $8,160 | 2022 Jan 6 |
Take TPST further
- Browse Pharmaceutical Stocks for the rest of the group, with what the businesses in it have in common and where they differ.
- Put TPST in a portfolio and see what it does to total return, drawdown, and how the rest of your holdings move with it. Compares against the S&P 500 over the same days, free and without an account.
- Screen for others like it by RSI, valuation, market cap, and insider activity.
- Check the earnings calendar for when Tempest Therapeutics, Inc. next reports.
Set alerts on TPST
Get notified when Tempest Therapeutics, Inc. hits your price targets or technical conditions are met.
Get Started Free